Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110344 · ClinicalTrials.gov registry record · Phase 2
Research Study for Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00110344 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 1 participants.
The verdict
NCT00110344, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.
Interventions
- DRUG Placebo
- DRUG Nexavar (Sorafenib, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110344
The ClinicalTrials.gov registry entry for NCT00110344 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00110344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110344 about?
NCT00110344 is a clinical study titled "Research Study for Patients With Metastatic Renal Cell Carcinoma". This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.
What is the current status of trial NCT00110344?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2005-11. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00110344?
The interventions under investigation include: Placebo (DRUG), Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00110344?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.